Starting Dose of PTH Conjugates
AssigneeAscendis Pharma Bone Diseases A/S
InventorsKennett Sprogøe, David Brian Karpf, Claus Strange
Life of this patent
Estimating the term…
Abstract
The present invention relates to a PTH conjugate, in which a PTH moiety is reversibly conjugated to a polymeric moiety or fatty acid-based moiety, or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said PTH conjugate or pharmaceutically acceptable salt thereof for use in the treatment, control, delay or prevention of a disease that can be treated, controlled, delayed or prevented with PTH, wherein the starting dose ranges from from 0.8 to 4.9 nmol/day and to the respective methods of treatment.
Claims30
A method of treating, controlling, delaying or preventing in a patient suffering from a disease which can be treated, controlled, delayed or prevented with PTH, wherein said method comprises the step of administering an effective amount of a PTH conjugate, in which a PTH moiety is reversibly conjugated to a polymeric moiety or fatty acid-based moiety, or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said PTH conjugate or pharmaceutically acceptable salt thereof to the patient starting dose ranging from 0.8 to 4.9 nmol/day.
(canceled)
Dependencies are inferred from the claim text.